Recent evidence on how anti-citrullinated protein antibodies, anti-modified protein autoantibodies and rheumatoid factor activity overlap in RA demonstrate new ideas for diagnostics and pathophysiology.
ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…
The 2020 Basic Science Year in Review covered autoantibody origin and persistence, insights into the major histocompatibility complex and factors in rheumatoid arthritis progression and relapse.
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.
ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
New diagnostic approaches combined with new evidence about pathogenesis are providing opportunities to help rheumatologists manage calcium pyrophosphate deposition disease.
Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.
Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.
A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.